Literature DB >> 21637300

Microbiological cure times in acanthamoeba keratitis.

C E Oldenburg1, J D Keenan, V Cevallos, M F Chan, N R Acharya, B D Gaynor, S D McLeod, E J Esterberg, T C Porco, T M Lietman.   

Abstract

AIMS: The purpose of this study was to estimate the duration of treatment necessary for sequential acanthamoeba laboratory tests from corneal scrapings to become negative, and to assess predictors that affect this duration period.
METHODS: We included all patients with at least one positive acanthamoeba culture or Giemsa stain at the F.I. Proctor Foundation Microbiology Laboratory from 1996 to 2009. A parametric survival analysis was performed among patients with repeat cultures to assess significant predictors for extended clearance time. Simulations were performed to estimate clearance time in the entire patient population, assuming imperfect sensitivity.
RESULTS: Thirty-seven patients with laboratory evidence of acanthamoeba had testing at 69 time points. The median clearance time among eyes with repeat cultures was 42.5 days (interquartile range (IQR) 22.0-82.0 days; unadjusted parametric model). Initial visual acuity was the only predictor significantly associated with clearance time in univariate analyses (P<0.0001). Using initial visual acuity as a predictor for clearance time among the entire patient population, the estimated clearance time decreased to 38.7 days (95% confidence interval (CI) 27.9-53.5 days). When the imperfect sensitivity of the culture technique was also taken into account, the estimated clearance time was 44.1 days (95% CI 31.9-61.0 days).
CONCLUSION: The duration of infection with acanthamoeba keratitis undergoing treatment has not been well characterized. In this report we estimate a median clearance time of approximately 6 weeks, with an IQR of 22-82 days.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21637300      PMCID: PMC3178241          DOI: 10.1038/eye.2011.126

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  16 in total

1.  Acanthamoeba: a difficult pathogen to evaluate and treat.

Authors:  William D Mathers
Journal:  Cornea       Date:  2004-05       Impact factor: 2.651

2.  Effects of corticosteroids in experimental Acanthamoeba keratitis.

Authors:  T John; J Lin; D Sahm; J H Rockey
Journal:  Rev Infect Dis       Date:  1991 Mar-Apr

Review 3.  Acanthamoeba keratitis: diagnosis and treatment update 2009.

Authors:  John K G Dart; Valerie P J Saw; Simon Kilvington
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

4.  Three cases of Acanthamoeba keratitis diagnosed and treated in the early stage.

Authors:  Nami Ueki; Hiroshi Eguchi; Yaeko Oogi; Hiroshi Shiota; Shinta Yamane; Hiromichi Umazume; Kenji Mizui
Journal:  J Med Invest       Date:  2009-08

5.  Effect of steroids on Acanthamoeba cysts and trophozoites.

Authors:  K McClellan; K Howard; J Y Niederkorn; H Alizadeh
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-11       Impact factor: 4.799

6.  Diagnosis of Acanthamoeba keratitis in vivo with confocal microscopy.

Authors:  K Winchester; W D Mathers; J E Sutphin; T E Daley
Journal:  Cornea       Date:  1995-01       Impact factor: 2.651

7.  Acanthamoeba keratitis: risk factors and outcome.

Authors:  C D Illingworth; S D Cook; C H Karabatsas; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-12       Impact factor: 4.638

8.  Persistently culture positive acanthamoeba keratitis: in vivo resistance and in vitro sensitivity.

Authors:  Juan J Pérez-Santonja; Simon Kilvington; Reanne Hughes; Adnan Tufail; Melville Matheson; John K G Dart
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

Review 9.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

10.  Delay in diagnosis and outcome of Acanthamoeba keratitis.

Authors:  I Claerhout; A Goegebuer; C Van Den Broecke; Ph Kestelyn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08       Impact factor: 3.117

View more
  3 in total

1.  Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts.

Authors:  Ricardo Lamy; Elliot Chan; Samuel D Good; Vicky Cevallos; Travis C Porco; Jay M Stewart
Journal:  Clin Exp Ophthalmol       Date:  2016-02-23       Impact factor: 4.207

2.  Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Anders Magnuson; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-19       Impact factor: 3.117

3.  Acute keratoconjunctivitis due to contamination of contact lens care solution with histamine-producing Raoultella species: A case report.

Authors:  Hiroshi Eguchi; Fumika Hotta; Tomomi Kuwahara; Haruyuki Nakayama-Imaohji; Shunji Kusaka; Yoshikazu Shimomura
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.